FibroGen Statistics

Total Valuation

FibroGen has a market cap or net worth of GBP 24.28 million. The enterprise value is 85.67 million.

Market Cap	24.28M
Enterprise Value	85.67M

Important Dates

The next estimated earnings date is Monday, May 5, 2025.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+2.82%
Shares Change (QoQ)	+0.31%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	92.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.03
PB Ratio	-0.17
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.25
EV / Sales	3.85
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.78

Financial Position

The company has a current ratio of 1.47

Current Ratio	1.47
Quick Ratio	0.60
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.65
Interest Coverage	-15.88

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-25.66%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-161.25%
Revenue Per Employee	105,157
Profits Per Employee	-168,910
Employee Count	225
Asset Turnover	0.09
Inventory Turnover	10.95

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -75.55% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-75.55%
50-Day Moving Average	0.40
200-Day Moving Average	0.47
Relative Strength Index (RSI)	48.03
Average Volume (20 Days)	10,377

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.41

Income Statement

In the last 12 months, FibroGen had revenue of GBP 23.66 million and -38.00 million in losses. Loss per share was -0.38.

Revenue	23.66M
Gross Profit	-65.21M
Operating Income	-104.61M
Pretax Income	-122.50M
Net Income	-38.00M
EBITDA	-102.46M
EBIT	-104.61M
Loss Per Share	-0.38

Full Income Statement

Balance Sheet

The company has 40.32 million in cash and 72.03 million in debt, giving a net cash position of -31.70 million.

Cash & Cash Equivalents	40.32M
Total Debt	72.03M
Net Cash	-31.70M
Net Cash Per Share	n/a
Equity (Book Value)	-146.68M
Book Value Per Share	-1.79
Working Capital	50.48M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -110.23 million and capital expenditures -212,473, giving a free cash flow of -110.44 million.

Operating Cash Flow	-110.23M
Capital Expenditures	-212,473
Free Cash Flow	-110.44M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is -275.59%, with operating and profit margins of -442.13% and -160.63%.

Gross Margin	-275.59%
Operating Margin	-442.13%
Pretax Margin	-517.76%
Profit Margin	-160.63%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.82%
Shareholder Yield	-2.82%
Earnings Yield	-156.54%
FCF Yield	-454.90%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FibroGen has an Altman Z-Score of -13.71. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.71
Piotroski F-Score	n/a